Literature DB >> 21327733

Bisphosphonate-induced osteonecrosis of the external ear canal: a retrospective study.

K Froelich1, A Radeloff1, C Köhler1, R Mlynski1, J Müller1, R Hagen1, N H Kleinsasser2.   

Abstract

In 2003, osteonecrosis of the jaw was described as an intraoral complication of bisphosphonate therapy. More recently, cases of avascular necrosis of the hip were reported in patients with long-lasting bisphosphonate therapy. Thus, it was the aim of the present study to analyze cases of benign osteonecrosis of the external ear canal and to retrospectively identify a possible relationship to long-lasting bisphosphonate therapy. 13 patients with osteonecrosis of the external ear canal operated on between 2005 and 2009 were included. Patient histories were reviewed for possible previous or current bisphosphonate therapy. Three patients with osteonecrosis of the external ear canal and long-term bisphosphonate therapy could be identified. They had been treated either for breast cancer or multiple myeloma. Certainly, the jaw is an area of increased risk for developing osteonecrosis with its high mechanical stress and intraoral bacterial flora. However, osteonecrosis of the hips and the external ear canal in patients receiving long-term bisphosphonate therapy necessitate further investigation of a possible systemic, bisphosphonate-related phenomenon.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327733     DOI: 10.1007/s00405-011-1496-z

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  41 in total

Review 1.  Diphosphonates. Experimental and clinical aspects.

Authors:  R G Russell; R Smith
Journal:  J Bone Joint Surg Br       Date:  1973-02

2.  Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giuseppe Avvisati; Giordano Dicuonzo; Fabrizio Battistoni; Michele Gavasci; Alfredo Salerno; Vincenzo Denaro; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

3.  Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.

Authors:  Cesar A Migliorati; Mark M Schubert; Douglas E Peterson; Luis Marcelo Seneda
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

4.  Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis.

Authors:  D Aguiar Bujanda; U Bohn Sarmiento; M A Cabrera Suárez; J Aguiar Morales
Journal:  Ann Oncol       Date:  2006-11-02       Impact factor: 32.976

5.  Benign osteonecrosis of the external ear canal.

Authors:  M Wolf; S Nusem-Horowitz; S T Zwas; A Horowitz; J Kronenberg
Journal:  Laryngoscope       Date:  1997-04       Impact factor: 3.325

6.  Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

Authors:  C Walter; M O Klein; A Pabst; B Al-Nawas; H Duschner; T Ziebart
Journal:  Clin Oral Investig       Date:  2009-03-18       Impact factor: 3.573

7.  Inhibition of oral mucosal cell wound healing by bisphosphonates.

Authors:  Regina Landesberg; Matthew Cozin; Serge Cremers; Victoria Woo; Stavroula Kousteni; Satrajit Sinha; LeeAnn Garrett-Sinha; Srikala Raghavan
Journal:  J Oral Maxillofac Surg       Date:  2008-05       Impact factor: 1.895

8.  Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis.

Authors:  Mark A Scheper; Ashraf Badros; Risa Chaisuparat; Kevin J Cullen; Timothy F Meiller
Journal:  Br J Haematol       Date:  2008-11-20       Impact factor: 6.998

9.  Benign osteitis of the external auditory meatus.

Authors:  R Youngs; P Kwok; M Hawke
Journal:  J Otolaryngol       Date:  1988-10

Review 10.  Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.

Authors:  M E Sarasquete; M González; J F San Miguel; R García-Sanz
Journal:  Oral Dis       Date:  2009-04-22       Impact factor: 3.511

View more
  6 in total

1.  Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative.

Authors:  Rebecca L Drieling; Andrea Z LaCroix; Shirley A A Beresford; Denise M Boudreau; Charles Kooperberg; Rowan T Chlebowski; Marcia G Ko; Susan R Heckbert
Journal:  J Am Geriatr Soc       Date:  2017-05-29       Impact factor: 5.562

2.  [Bilateral bisphosphonate-associated osteonecrosis of the external ear canal : a rare case].

Authors:  F Bast; H Fuss; T Schrom
Journal:  HNO       Date:  2012-12       Impact factor: 1.284

Review 3.  Bisphosphonate Related Osteonecrosis of the Jaw: An Update.

Authors:  Vijay Kumar; Raman Kant Sinha
Journal:  J Maxillofac Oral Surg       Date:  2013-08-09

Review 4.  External auditory canal and middle ear cholesteatoma and osteonecrosis in bisphosphonate-treated osteoporosis patients: a Danish national register-based cohort study and literature review.

Authors:  A-L Thorsteinsson; P Vestergaard; P Eiken
Journal:  Osteoporos Int       Date:  2014-03-25       Impact factor: 4.507

Review 5.  Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Sven Otto; Suad Aljohani; Riham Fliefel; Sara Ecke; Oliver Ristow; Egon Burian; Matthias Troeltzsch; Christoph Pautke; Michael Ehrenfeld
Journal:  Medicina (Kaunas)       Date:  2021-05-09       Impact factor: 2.430

6.  Zoledronate-Associated Osteonecrosis of the Jaw in a Dog with Appendicular Osteosarcoma.

Authors:  A P Lundberg; P J Roady; A J Somrak; M E Howes; T M Fan
Journal:  J Vet Intern Med       Date:  2016-06-14       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.